UGT1A1 and colorectal cancer: Therefore, this study was designed to observe the difference in the adverse reaction spectrum to CPT-11 in panneoplastic and colorectal cancer patients with heterozygous mutation of UGT1A1 and the impact of dose reduction of CPT-11 on efficacy and prognosis in these patients.